Cardiff Oncology, Inc. will be holding a conference call on Thursday, May 2 at 4:30 p.m. ET/1:30 p.m. PT in San Diego. The company, a clinical-stage biotechnology company, focuses on developing novel therapies using PLK1 inhibition for various types of cancers. They are set to release their financial results for the first quarter ended March 31, 2024 on May 2 after the close of trading.
During the conference call and webcast on May 2, individuals interested in listening can do so using the webcast link in the “Investors” section of Cardiff Oncology’s website. A replay of the call will be available in the investor relations section of the website after the call is completed.
Cardiff Oncology’s lead asset is onvansertib, a PLK1 inhibitor currently undergoing evaluation in combination with standard-of-care therapeutics for various indications such as RAS-mutated metastatic colorectal cancer and metastatic pancreatic ductal adenocarcinoma. The company’s development strategy is designed to target tumor vulnerabilities to overcome treatment resistance and deliver better clinical outcomes. More information can be found on Cardiff Oncology’s website.
For further information, individuals can contact Cardiff Oncology’s Chief Financial Officer, James Levine, at 858-952-7670. Investors can contact Kiki Patel, PharmD at Gilmartin Group, and media inquiries can be directed to Grace Spencer at Taft Communications.